+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Desktop Type, Portable Type), By Application (Hospital, Blood Center, Clinic, Others), By End User (Diagnostic Laboratories, Blood Donation Organizations, Research Institutions), By Technology (Ultrasound-Guided, Laser-Guided, AI & Image Recognition), By Automation Level (Semi-Automated, Fully Automated, Hybrid Systems), and Regional Forecast, 2026-2034
The global blood collecting robot market was valued at USD 50.1 million in 2025 and is estimated at USD 56.7 million in 2026. The market is projected to reach USD 152.9 million by 2034, representing a 13.2% CAGR during 2026–2034.
Blood collecting robots automate key steps in venipuncture by combining vein localization, imaging, needle guidance, robotic positioning and sample-handling controls. The commercial proposition is strongest where health systems face high blood-draw volumes, staffing pressure and demand for standardized procedures that can reduce dependence on manual technique.
Regulatory progress has moved the category from experimental automation toward commercial medical-device deployment. In August 2026, FDA authorized Aletta as the first standalone robotic device in the United States to draw blood without hands-on needle insertion by a phlebotomist, establishing a concrete regulatory pathway for a market that had previously been centered on prototypes, pilots and European commercialization.
The market remains early-stage, so adoption depends on workflow fit as much as technical success. Hospitals and outpatient laboratories must evaluate first-stick performance, exception handling, patient acceptance, throughput, staffing models, maintenance, consumables and integration with existing collection processes. Vendors able to prove clinical reliability and economical throughput can expand the addressable market beyond innovation centers into routine diagnostic settings.
Source: U.S. FDA — Aletta authorization; U.S. Bureau of Labor Statistics — Phlebotomists; World Health Organization — Blood safety and availability.
The study covers robotic systems designed to automate or materially assist venous blood collection, with analysis by device type, application, end user, guidance technology, automation level and geography.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million |
| By Type | Desktop Type; Portable Type |
| By Application | Hospital; Blood Center; Clinic; Others |
| By End User | Diagnostic Laboratories; Blood Donation Organizations; Research Institutions |
| By Technology | Ultrasound-Guided; Laser-Guided; AI & Image Recognition |
| By Automation Level | Semi-Automated; Fully Automated; Hybrid Systems |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States, Canada, Netherlands, Denmark, Germany, United Kingdom, France, China, Japan, India, South Korea, Australia, Brazil, GCC countries, South Africa and other major markets |
| Key Market Players | BHealthCare; VascuLogic; Vitestro; Beijing Magic Nurse Robotics Co., Ltd.; Nigale; TruTouch Technologies; Veebot; Microbot Medical |
The market includes robotic or robot-assisted systems whose core commercial function is locating venous access and performing or guiding blood collection. Revenue may include the robotic platform, integrated imaging and control subsystems, and directly associated system software supplied as part of the collection device.
Conventional manual phlebotomy supplies, standard blood-collection tubes, laboratory analyzers, non-robotic vein finders and general robotic platforms without a dedicated blood-collection function are outside the core revenue boundary unless discussed as workflow complements or technology substitutes.
The U.S. Bureau of Labor Statistics reported 143,900 phlebotomist jobs in 2025 and projects 18,000 openings each year over 2025–2035. Automation does not remove the need for trained personnel, but robotic blood draw can change how staff supervise routine collections and may allow skilled workers to focus on difficult patients, exceptions and other clinical tasks.
FDA authorized the Aletta Autonomous Robotic Phlebotomy Device in August 2026 through the De Novo pathway. The decision establishes a U.S. device classification for autonomous robotic phlebotomy and gives later entrants a clearer regulatory reference point than existed during the market's prototype phase.
WHO reports 120.4 million blood donations globally, illustrating the scale of blood-collection activity before routine diagnostic draws are even considered. Hospitals, laboratories, blood centers and outpatient clinics therefore represent multiple high-volume environments where automation can be evaluated on throughput and staffing economics.
Venipuncture is a repetitive procedure but not a uniform one. Anatomical variability, patient movement, pediatric or difficult-access cases, anxiety and exception handling mean automated systems must demonstrate dependable real-world performance before institutions will redesign phlebotomy workflows around them.
The market is shifting from proof-of-concept robotics toward regulated clinical products supported by multicenter evidence, commercial partnerships and dedicated deployment models.
FDA's August 2026 authorization of Aletta is a category-defining event because it moves autonomous venipuncture into a regulated U.S. outpatient pathway. Competitors can now benchmark development programs against a real commercial classification.
Vitestro published a peer-reviewed multicenter clinical study in 2026, strengthening the evidence base for autonomous blood drawing. Larger clinical datasets are essential for buyers evaluating safety, first-attempt success and workflow performance beyond controlled pilot sites.
Vitestro obtained CE marking in 2024 for autonomous blood drawing, supporting commercial use in Europe. Early deployments in the Netherlands and Denmark provide a practical reference for staffing models, patient acceptance and integration in diagnostic workflows.
Autonomous phlebotomy companies are moving beyond research-stage financing toward commercialization capital. Funding supports manufacturing scale-up, clinical programs, regulatory submissions and customer deployment infrastructure needed to expand beyond a small number of pilot sites.
The highest-value opportunity through 2034 is likely to be routine high-volume blood collection where workflow standardization can translate technical autonomy into measurable labor productivity and patient-service gains.
Blood-collection robotics depends on the integration of imaging, vascular localization, robotic motion control and decision software rather than on one enabling technology alone.
Ultrasound can provide depth and vessel information that supports access planning in patients whose veins are difficult to identify visually. Integration with robotic control can improve localization before needle insertion.
Optical and laser-guided approaches can identify superficial vascular patterns and support alignment. These systems may be simpler for selected patients but can be more dependent on anatomy and tissue characteristics.
AI and image-recognition tools can assist vessel selection, trajectory planning and real-time monitoring. Their value increases when software is trained and validated across diverse patient populations and difficult-access conditions.
Semi-automated and hybrid systems retain greater human control, while fully automated systems aim to handle localization, needle positioning and collection with limited direct intervention. Regulatory requirements and workflow confidence become more demanding as autonomy increases.
Type segmentation reflects whether the robotic blood-draw platform is designed primarily for fixed high-throughput installation or for greater movement between care locations.
Desktop systems hold the stronger current position because early autonomous phlebotomy is concentrated in fixed outpatient and laboratory environments where the device can be integrated with a controlled patient station, power supply and specimen workflow.
Portable systems can expand access across clinics, wards and decentralized collection settings, but portability must be balanced against robotic stability, imaging requirements and safe needle-control architecture. Commercial growth depends on achieving mobility without reducing procedural reliability.
Desktop platforms are expected to remain important during early commercialization, while portable designs can broaden the addressable market as systems become smaller and workflow integration matures.
Application demand varies according to collection volume, staffing model, patient complexity and the economics of redesigning the venipuncture workflow.
Hospitals provide large blood-draw volumes and difficult-access cases but also complex workflows and stricter integration requirements. Robotic systems must coordinate with phlebotomy teams, nursing workflows and specimen transport while demonstrating reliable exception handling.
Blood centers offer repetitive collection processes and defined patient flows that can support automation evaluation. Adoption depends on throughput, donor comfort, collection protocol compatibility and the economics of capital deployment.
Clinics and outpatient laboratories are attractive because scheduled blood draws can be standardized around dedicated collection stations. FDA's first U.S. autonomous authorization specifically targets adults in outpatient settings, supporting this application pathway.
Other applications include research, specialty diagnostic and institutional settings where automated vascular access can support a defined workflow. Commercial viability depends on procedure volume and the value of reducing manual variability.
Outpatient diagnostic workflows are likely to be an important early commercial beachhead because they combine repeatable procedures with clearer staffing and throughput economics.
End-user economics differ according to testing volume, blood-donation workflow and the degree to which automated collection can be integrated into existing operations.
Diagnostic laboratories are a central target because blood collection is directly linked to high-volume testing workflows. Autonomous collection can be evaluated against queue time, staffing needs, first-attempt success and sample-handling consistency.
Blood-donation organizations manage standardized collection processes at meaningful scale. WHO's 120.4 million annual global donations highlight the size of the broader collection ecosystem, although donor-specific protocols create distinct technical requirements from routine diagnostic phlebotomy.
Research institutions support technology development, clinical validation and specialized vascular-access studies. Their direct revenue contribution is smaller than diagnostic deployment, but they remain important for performance evidence and next-generation system development.
Diagnostic laboratories are expected to remain the most commercially significant end-user group as regulatory authorization and clinical evidence support routine outpatient adoption.
Technology segmentation captures the primary sensing and guidance approach used to identify vessels and control robotic needle placement.
Ultrasound-guided robotics can assess vessel position below the skin surface and support difficult-access patients. Its commercial value is strongest when imaging can be integrated quickly into a repeatable automated workflow.
Laser or optical guidance can assist superficial vein visualization and alignment. These solutions can support simpler system architectures for selected use cases but may face limitations in patients with less visible or deeper vessels.
AI and image recognition can combine multiple image inputs to support vessel selection, motion control and procedural monitoring. Competitive differentiation depends on validated algorithms, diverse training data and consistent performance in real clinical conditions.
AI and multimodal imaging are likely to become increasingly important as vendors seek higher first-attempt reliability and broader patient eligibility without adding extensive manual intervention.
Automation level determines how responsibility is divided between the robotic platform and trained clinical staff.
Semi-automated systems assist localization, alignment or needle control while preserving direct human decision-making for key steps. This can lower adoption barriers in settings that want robotic consistency without fully redesigning staff responsibility.
Fully automated platforms represent the highest-growth strategic direction because they aim to perform blood draws with limited hands-on intervention. FDA authorization of Aletta demonstrates that this model has reached regulated U.S. commercialization for selected outpatient adults.
Hybrid systems combine automated guidance with human confirmation or intervention points. They can be attractive where institutions want automation benefits while maintaining manual control for exceptions, difficult access or patient-specific concerns.
Fully automated systems can capture the largest long-term productivity opportunity, but semi-automated and hybrid models may remain important where clinical teams prefer phased adoption.
Regional analysis focuses on where regulatory authorization, clinical validation, laboratory scale and staffing economics create a differentiated commercial environment. Country spotlights are selective and tied to concrete market-relevant evidence.
North America remains the largest regional market because the United States combines high diagnostic testing volume, staffing pressure, medical-device investment and the first FDA authorization of a standalone autonomous robotic blood-draw device. The region provides a strong environment for evaluating whether robotic venipuncture can translate technical performance into scalable outpatient productivity.
FDA authorized the Aletta Autonomous Robotic Phlebotomy Device on August 19, 2026, and the agency states that one trained phlebotomist may oversee up to three devices. BLS reported 143,900 phlebotomist jobs in 2025, making staffing productivity and supervised automation commercially relevant to large laboratory networks.
Europe has played an important role in moving automated blood drawing from clinical research into commercial use. CE-marked systems and early deployments provide real-world references for patient acceptance, staffing models and laboratory workflow integration, while European regulatory requirements still demand strong clinical and technical documentation.
Vitestro announced CE marking for its autonomous blood-drawing device in August 2024, enabling commercial use in Europe, with early implementation centered in the Netherlands and Denmark. These deployments provide practical evidence for how autonomous collection can be integrated into routine outpatient laboratory operations.
Source: Vitestro — CE Marking.
Asia-Pacific offers significant long-term potential through large urban diagnostic volumes, healthcare labor constraints and active medical-robotics development in China, Japan, South Korea and other markets. Adoption will depend on local regulatory pathways, capital budgets and whether systems can be manufactured and serviced at economics suited to high-volume regional laboratories.
Latin America remains an emerging market for robotic blood collection. Large urban laboratory networks can create concentrated demand, but capital cost, technical service coverage and the availability of trained phlebotomy personnel will determine whether automation is economical compared with established manual workflows.
Middle East & Africa is highly uneven. Advanced Gulf healthcare systems may adopt robotic phlebotomy as part of broader smart-hospital investment, while many African markets remain more constrained by capital budgets and basic laboratory infrastructure. Commercial entry therefore requires selective targeting rather than a uniform regional strategy.
Aletta received De Novo authorization in August 2026 under a new device classification for autonomous robotic phlebotomy. This reduces regulatory uncertainty for the category and gives future entrants a defined precedent for safety, performance and labeling expectations.
Vitestro announced CE marking for autonomous blood drawing in August 2024, allowing commercialization in Europe. CE-marked deployment gives healthcare providers an operating reference before the category reaches broad penetration.
Vitestro reported publication of a multicenter study in Clinical Chemistry in April 2026. As systems move into routine care, buyers and regulators are likely to place increasing weight on multicenter performance, first-attempt success, adverse events and workflow outcomes rather than single-site demonstrations.
Early regulatory indications focus on defined adult outpatient use rather than every blood-draw scenario. Pediatric, inpatient, difficult-access and emergency workflows can require additional validation, which limits near-term addressable deployment but creates a staged expansion pathway.
Competition remains fragmented because the category is transitioning from robotics development to regulated clinical commercialization.
Vitestro and other dedicated developers are building integrated systems around vascular imaging, robotic needle guidance and automated collection. Regulatory progress and clinical evidence increasingly separate commercial-ready platforms from laboratory prototypes.
VascuLogic, Veebot, BHealthCare and related companies compete through combinations of ultrasound, imaging, motion control and robotic access. Technical differentiation centers on successful vessel identification and consistent needle placement across diverse patients.
Beijing Magic Nurse Robotics, Nigale and other regional developers can benefit from large domestic healthcare markets and lower-cost engineering bases. Their international expansion will depend on regulatory evidence, manufacturing quality and distributor support.
The competitive hierarchy through 2034 will be shaped less by prototype novelty and more by regulatory clearances, multicenter clinical performance, manufacturing scale, uptime, service networks and measurable workflow economics.
| Date | Development | Market Implication |
|---|---|---|
| August 2026 | FDA authorized the Aletta Autonomous Robotic Phlebotomy Device through the De Novo pathway as the first standalone U.S. robotic device for hands-off blood drawing in selected adults. | Creates a formal U.S. regulatory category and materially advances autonomous phlebotomy from development into regulated commercial use. |
| April 2026 | Vitestro announced publication of a peer-reviewed multicenter clinical study of autonomous blood drawing in Clinical Chemistry. | Strengthens the evidence base needed for hospital and laboratory procurement and supports broader regulatory confidence. |
| March 2025 | Northwestern Medicine and Vitestro announced collaboration on a U.S. clinical trial of autonomous blood drawing. | Expanded U.S. clinical validation and supported the pathway toward domestic regulatory and commercial entry. |
| August 2024 | Vitestro announced CE marking for its autonomous blood-drawing device. | Enabled commercial use in Europe and established an early reference market for deployment of autonomous phlebotomy. |
The market is projected to reach USD 152.9 million by 2034 as regulatory authorization, clinical validation and laboratory automation expand the number of sites willing to evaluate autonomous venipuncture.
Early growth is likely to concentrate in high-volume outpatient laboratories and health systems where staffing pressure, queue management and standardized workflows can support a clear return-on-investment case. Broader adoption into inpatient, pediatric and difficult-access populations will require additional evidence and workflow validation.
Commercial leadership will depend on the ability to convert technical performance into reliable daily operations. Vendors must demonstrate safe first-attempt access, exception handling, patient acceptance, system uptime, maintenance support and integration with specimen-management processes while keeping per-draw economics competitive with manual collection.
2025 base-year value, 2026 estimate, 2034 forecast and 2026–2034 CAGR under the fixed report framework.
Type, application, end user, guidance technology and automation-level analysis with commercial positioning of major subsegments.
Five major regions with selective country evidence tied to regulation, commercialization, staffing and diagnostic-workflow economics.
Specialist robotics developers, commercialization readiness, regulatory differentiation and verified company developments.
Workforce pressure, blood-collection volume, clinical reliability, patient workflow and laboratory automation drivers and constraints.
FDA De Novo authorization, European CE marking, peer-reviewed validation and staged market-access considerations.
Market sizing combines the supplied report model with bottom-up review of autonomous phlebotomy platforms, application settings, end-user categories and regional commercialization. The public framework normalizes headline values to 2025, 2026 and 2034 while retaining the report's supplied segmentation dimensions.
Secondary research prioritizes regulators, government labor statistics, global health authorities, peer-reviewed literature and company primary sources. FDA authorization materials, BLS workforce data, WHO blood-collection indicators and company regulatory announcements are used to interpret adoption and market access. Market-research and report-selling websites are excluded as evidence.
Forecast assumptions consider regulatory approvals, multicenter clinical validation, laboratory automation investment, staffing pressure, platform throughput, patient acceptance, manufacturing scale, service economics and geographic rollout. No country market share or CAGR is inferred from patient population or workforce data.
The global market is estimated at USD 56.7 million in 2026 and is projected to reach USD 152.9 million by 2034, representing a 13.2% CAGR during 2026–2034.
North America is the largest regional market, supported by U.S. regulatory authorization, large diagnostic networks, healthcare automation investment and phlebotomy staffing needs.
Growth is driven by laboratory automation, staffing pressure, high blood-draw volumes, progress in vascular imaging and robotic control, and the transition from pilot systems to regulated commercial devices.
On August 19, 2026, FDA authorized the Aletta Autonomous Robotic Phlebotomy Device through the De Novo pathway, creating the first U.S. authorization for a standalone hands-off robotic blood-draw device in selected adults.
The report covers hospitals, blood centers, clinics and other relevant applications, with additional analysis by end user, technology, device type and automation level.
The technology segmentation includes ultrasound-guided, laser-guided and AI and image-recognition approaches used for vessel localization and robotic procedure control.
The profiled companies include BHealthCare, VascuLogic, Vitestro, Beijing Magic Nurse Robotics, Nigale, TruTouch Technologies, Veebot and Microbot Medical.
The forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
